ZNTL
What one share of Zentalis Pharmaceuticals holds
Pharmaceutical Preparations
We are a clinical-stage biopharmaceutical company developing azenosertib (ZN-c3), an investigational, potentially first-in-class and best-in-class WEE1 inhibitor, for patients with ovarian cancer and other tumor types. In clinical trials, azenosertib has been well tolerated and has demonstrated anti-tumor activity as a single agent across multiple tumor types.
Zentalis Pharmaceuticals’s numbers from its SEC filings, divided by its shares. Results cover the last 12 months to 2026-06-30; the balance sheet is as of 2026-06-30.
| Profit | −$1.96 |
|---|---|
| Capex (buildings and equipment) | $0.00 |
| Free cash flow | −$1.80 |
| Cash and investments | $0.35 |
| Book value | $2.00 |
Per share by fiscal year
| Year | Sales | Profit | Capex | Free cash | Dividends | Book value |
|---|---|---|---|---|---|---|
| 2019 | — | −$8.16 | $0.06 | −$7.06 | — | −$13.09 |
| 2020 | — | −$4.19 | $0.03 | −$3.12 | — | $7.52 |
| 2021 | — | −$3.72 | $0.14 | −$3.75 | — | $8.00 |
| 2022 | $0.00 | −$4.48 | $0.05 | −$3.15 | — | $7.32 |
| 2023 | $0.00 | −$4.47 | $0.01 | −$3.19 | — | $6.18 |
| 2024 | $0.95 | −$2.33 | $0.00 | −$2.41 | — | $4.73 |
| 2025 | $0.00 | −$1.91 | $0.00 | −$1.74 | — | $3.13 |